Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 11/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | LTA4H | P09960 | 4/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6438293 | 1.00 | ACE (0.65) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL6436563 | 1.00 | ACE (0.65) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL6436560 | 1.00 | ACE (0.65) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL10659497 | 0.95 | ACE (0.61) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL11052819 | 0.86 | ACE (0.58) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL19369794 | 0.86 | ACE (0.53) | ACELMNALTA4HSMN1; SMN2ACE2 | |
| SCHEMBL3732909 | 0.85 | ACE (0.52) | ACELMNALTA4HACE2 | |
| SCHEMBL7087531 | 0.83 | ACE (0.56) | ACELMNALTA4HACE2 | |
| SCHEMBL29290359 | 0.83 | ACE (0.56) | ACELMNALTA4HACE2 | |
| SCHEMBL10786135 | 0.81 | ACE (0.56) | ACELMNALTA4HACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ACE 234/4885LMNA 993/4885LTA4H 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.